Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India

Autor: Subrat K. Acharya, Baibaswata Nayak, Sreejith Vasudevan, Bhaskar Thakur, Shalimar, Siddhartha Datta Gupta, Subrat Kumar Panda, Nancy Kalra, Prasenjit Das, A. Kavimandan
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Liver Cirrhosis
Male
Cirrhosis
Sustained Virologic Response
Hepacivirus
genotype
Erythropoietin - fibrosis - genotype - peginterferon - ribavirin - sofosbuvir
lcsh:Medicine
Polyethylene Glycols
Tertiary Care Centers
chemistry.chemical_compound
0302 clinical medicine
Genotype
Medicine
030212 general & internal medicine
peginterferon
biology
virus diseases
General Medicine
Hepatitis C
Middle Aged
Recombinant Proteins
030211 gastroenterology & hepatology
Original Article
Female
Adult
medicine.medical_specialty
ribavirin
Alpha interferon
India
Interferon alpha-2
sofosbuvir
General Biochemistry
Genetics and Molecular Biology
03 medical and health sciences
Insulin resistance
Internal medicine
Humans
Risk factor
Erythropoietin
Aged
business.industry
Ribavirin
lcsh:R
fibrosis
Interferon-alpha
Hepatitis C
Chronic
medicine.disease
biology.organism_classification
Surgery
chemistry
business
Zdroj: The Indian Journal of Medical Research
Indian Journal of Medical Research, Vol 143, Iss 3, Pp 331-340 (2016)
ISSN: 0971-5916
Popis: Background & objectives: Standard of care for chronic hepatitis C (CHC) in India is peginterferon and ribavirin (RBV). The response to treatment in real life stetting is unclear. The objectives of this study were to evaluate the demographic profile and assess the virological response and predictors of response in CHC patients. Methods: Consecutive patients with CHC were included in this study. Detailed clinical history, risk factors, and predictive factors of response were noted. Patients were treated with peginterferon α2b (1.5 µg/kg/wk) and RBV (12 mg/kg/day) for 6 to 18 months based on response. Results: A total of 211 patients were included in the analysis, mean age 40.6±12.3 yr, 144 (68%) were males and 71 (34%) had compensated cirrhosis. Commonest risk factor for acquiring CHC was previous transfusion and surgery (51%). Genotype 3 (72%) was most common followed by genotype 1 (23%). Overall sustained virologic response (SVR) was 64 per cent [95% CI 57.1%-70.4%]. The SVR was 66.5 per cent [95% CI 58.34-73.89%] for genotype 3 and 61.2 per cent [95% CI 46.23 to 74.80%] for genotype 1. Non-cirrhotics had better SVR rates compared to cirrhotics (76 vs 41%, p2 were predictors of low SVR. Interpretation & conclusions: Genotype 3 was the commonest HCV genotype. The commonest source of infection was previous transfusion and surgery. SVR rates for genotypes 3 were better than genotype 1 patients. Predictors of non-response were high BMI, insulin resistance, significant fibrosis and inadequate compliance.
Databáze: OpenAIRE
Externí odkaz: